Recursion Pharmaceuticals is trading at $3.38 (5.1% down) amid a broader pullback in high-beta biotech and risk assets.
- The move aligns with a decline in the Biotech ETF (XBI) and major indices as investors rotate out of growth stocks due to geopolitical tensions.
- Recent insider selling in July and a weak Q1 2026 revenue profile continue to weigh on investor sentiment despite no new company-specific catalysts reported today.